Bluebird Bio

GPTKB entity

Statements (65)
Predicate Object
gptkbp:instance_of gptkb:biotechnology
gptkbp:acquisition gptkb:Celgene_Corporation
gptkbp:awards Best Places to Work
Innovative Company Award
Top 100 Biotech Companies
gptkbp:ceo gptkb:Andrew_Obenshain
gptkbp:clinical_trial gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:Japan
gptkb:United_States
gptkb:Lenti_Globin
gptkb:Skysona
gptkb:Zynteglo
Phase 2
Phase 3
Phase 1/2
gptkbp:collaboration gptkb:Harvard_University
gptkb:University_of_Pennsylvania
gptkb:Children's_Hospital_of_Philadelphia
gptkbp:financials publicly traded
market cap over $1 billion
revenue from gene therapies
gptkbp:focus gptkb:gene_therapy
gptkbp:focus_area gptkb:Oncology
rare diseases
severe genetic diseases
gptkbp:focuses_on gptkb:gene_therapy
gptkbp:founded gptkb:2010
gptkbp:founded_in gptkb:1992
gptkbp:founder gptkb:Nick_Leschly
gptkbp:funding gptkb:venture_capital
gptkbp:has_part gptkb:film_production_company
research and development
clinical trials
business development
regulatory affairs
commercial operations
gptkbp:has_product gptkb:Skysona
gptkb:Zynteglo
gptkbp:headquarters gptkb:Cambridge,_Massachusetts
https://www.w3.org/2000/01/rdf-schema#label Bluebird Bio
gptkbp:investment $1.5 billion
gptkbp:mission transform lives through gene therapy
gptkbp:number_of_employees 200-500
gptkbp:partnership gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Novartis
gptkbp:product Lenti Globin for beta-thalassemia
Skysona for cerebral adrenoleukodystrophy
Zynteglo for beta-thalassemia
gptkbp:regulatory_compliance gptkb:FDA
gptkb:European_Medicines_Agency
gptkbp:research_focus genetic disorders
oncology
immunology
gptkbp:stock_symbol BLUE
gptkbp:technology Lentiviral vector
gptkbp:traded_on gptkb:NASDAQ
gptkbp:vision a world where genetic diseases are treated effectively.
gptkbp:website bluebirdbio.com
gptkbp:bfsParent gptkb:BLU-701
gptkb:Bayer_AG
gptkbp:bfsLayer 5